Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Vesivax Vaccine Formulation Against Neisseria Gonorrhoeae - Project Summary the Principal Goal of This Project Is to Develop a Vesivax®-based Vaccine Against Neisseria Gonorrhoeae (NG). the Studies Proposed in This Sbir Phase I Application Will Be Focused on Co-formulating an Newly Identified Surface-displayed Outer Membrane NG Protein, Mtre, With Various Immunostimulatory Adjuvant Molecules (IAMS) in the Vesivax® Liposomal Platform. We Will Characterize the Immunogenicity of These Vesivax®-mtre-iam Formulations in Mice, and Select for the Best Candidates to Be Further Evaluated in a Novel Mouse Upper Reproductive Tract NG Infection Model. These Studies Will Elucidate the Immunological Profile in a Vaccine That Will Correlate With Protective Immunity Against NG.
Committed
$599,596
Paid out
$575.3K
96%
Committed, not yet paid
$24.3K
4%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…